NPS Pharmaceuticals Reports NatparaTM Phase 3 Results to be Presented at ENDO, the annual meeting of The Endocrine Society
NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) today reported that three abstracts related to the Phase 3 REPLACE study of Natpara™ in hypoparathyroidism will be presented at ENDO 2012, the annual meeting of The Endocrine Society in Houston, TX, June 23-26, 2012.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.